iOmx Therapeutics AG

Receive alerts
Market Cap:
52 weeks high
52 weeks low

In brief

iOmx Therapeutics is a biopharmaceutical company focused on developing first-in-class cancer immuno-therapeutics addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high throughput screening platform, iOmx has identified a number of proprietary tumor-associated immune checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies, including PD-1/PD-L1 checkpoint inhibitors. Founded in 2016 based on the work of its scientific founders Philipp Beckhove, M.D., and Nisit Khandelwal, Ph.D., conducted at the German Cancer Research Center, iOmx has been funded by MPM Capital (both its BV2014 and UBS Oncology Impact Funds), Sofinnova Partners, Wellington Partners and Merck Ventures and is based in Martinsried / Munich, Germany.